Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced an exclusive five-year global supply agreement for NO and NO2 (Nitrogen Dioxide) calibration gas with MESA Specialty Gases & Equipment.
Key Highlights
-
Five year term begins on the earlier of FDA approval for the LungFit™ PH system or December 31, 2020
-
Beyond Air will be responsible for the initial and future costs for adjustments to MESA facilities to meet capacity requirements (estimated to be less than $100,000)
-
Beyond Air has the option to have MESA design and operate a calibration gas manufacturing facility dedicated to Beyond Air
-
Deal is exclusive on a global basis to both companies
How Architects Shape the Future of Healthcare Facilities
UNC Health, Duke Health Form Partnership for Stand-alone Children's Hospital
Sarasota Memorial Hospital Plans to Build New Facility in North Port
CMMS, Data and the Path to Compliance
Healthcare is a Major Ransomware Target